Siga Technologies ( (SIGA) ) has released its Q2 earnings. Here is a breakdown of the information Siga Technologies presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on developing innovative medicines to treat and prevent infectious diseases, with a primary focus on orthopoxviruses such as smallpox.
In its latest earnings report for the second quarter of 2025, SIGA Technologies announced significant financial achievements, including substantial product revenues and additional development funding. The company reported $79 million in product revenues for the quarter, marking a significant increase from the previous year.
Key highlights from the report include $53 million in oral TPOXX sales and $26 million in IV TPOXX sales, primarily due to deliveries to the Strategic National Stockpile. Additionally, SIGA received $27 million in development funding under the BARDA 19C contract, which includes $13 million for the TPOXX pediatric program and $14 million for manufacturing support. These developments underscore the company’s strong business model and the value of its flagship product, TPOXX, in treating smallpox.
Looking ahead, SIGA Technologies remains focused on expanding its product offerings and securing further government contracts. The management’s outlook suggests a continued emphasis on leveraging partnerships and funding to advance its mission of combating severe infectious diseases globally.